Pentagon Eyes Search for Virus-Fighting Protein ‘Cocktails’

Diane Barnes
Add to Briefcase
See more stories about...
Diane Barnes
Oct. 4, 2013, 10:02 a.m.

WASH­ING­TON — The U.S. De­fense De­part­ment is weigh­ing a new search for im­mune-pro­tein “cock­tails” it hopes will pro­tect hu­mans against Ebola and oth­er deadly, weapon-us­able vir­uses.

The Pentagon two weeks ago in­vited sci­ent­ists to sub­mit re­search pro­pos­als for design­ing “mono­clonal an­ti­bod­ies” that could pro­tect against Ebola and Mar­burg, as well as “al­phavir­uses” such as Venezuelan equine en­ceph­al­it­is.

Pentagon plan­ners have been turn­ing to an­ti­bod­ies as a pos­sible tool be­cause “no easy and quick fix” for such agents has emerged from ef­forts to de­vel­op vac­cines or tra­di­tion­al an­ti­vir­al treat­ments, said Gigi Gron­vall, a seni­or as­so­ci­ate with the Cen­ter for Health Se­cur­ity at the Uni­versity of Pitt­s­burgh Med­ic­al Cen­ter.

The early-stage re­search now un­der con­sid­er­a­tion ideally would lead to single-shot treat­ments cap­able of guard­ing troops for months from mul­tiple vir­us types, the De­fense Threat Re­duc­tion Agency said in a Sept. 18 so­li­cit­a­tion. DTRA of­fi­cials wel­comed re­search­ers to pro­pose “‘cock­tails’ that may en­able cross-pro­tec­tion against mul­tiple spe­cies of vir­us.”

The em­phas­is on “cock­tails” makes the latest DTRA pro­pos­al par­tic­u­larly not­able, be­cause sev­er­al stud­ies sug­gest that mixes of sev­er­al an­ti­bod­ies can be par­tic­u­larly ef­fect­ive in fight­ing patho­gens, Gron­vall told Glob­al Se­cur­ity News­wire in a tele­phone in­ter­view. An­ti­bod­ies hit their tar­gets with such spe­cificity that a treat­ment with mul­tiple im­mune pro­teins can help ac­count for slight vari­ations between in­vad­ing mi­crobes.

Mono­clonal an­ti­bod­ies have been in use since the 1980s to treat can­cer and im­mune-linked ail­ments such as rheum­at­oid arth­rit­is, but their use against in­fec­tious patho­gens has lagged, ac­cord­ing to a DTRA-sponsored re­port co-au­thored by Gron­vall on the tech­no­logy’s biode­fense po­ten­tial.

The United States last year li­censed the first in­hal­a­tion an­thrax treat­ment to use the tech­no­logy, which in­volves cre­at­ing massive quant­it­ies of a single im­mune “an­ti­body.” The hu­man body nat­ur­ally gen­er­ates such pro­teins, each of which is de­signed to mark a spe­cif­ic patho­gen or tox­in for elim­in­a­tion by oth­er im­mune-sys­tem com­pon­ents.

One an­ti­body cock­tail grown in mod­i­fied to­bacco plants showed prom­ising po­tency against Ebola in­fec­tions spe­cific­ally, ac­cord­ing to a study pub­lished in Au­gust.

“There have been a lot of changes in the way that mono­clonal an­ti­body tech­no­lo­gies have evolved over the last sev­er­al years, and it makes mono­clonal an­ti­bod­ies a very nice piece of their ap­proach to med­ic­al coun­ter­meas­ures,”  Gron­vall said.

The latest DTRA Broad Agency An­nounce­ment seeks pro­pos­als for stud­ies no longer than one year, with a cost no great­er than $500 mil­lion. The fil­ing dead­line is Oct. 16.

What We're Following See More »
CARSON UP NEXT
Zinke Confirmed As Interior Secretary
1 hours ago
BREAKING
GOODLATTE SENDING LETTER TO SESSIONS THIS WEEK
House GOP Blocks Dems on Trump Ethics
3 hours ago
THE DETAILS

On a party-line vote, "the House Judiciary Committee defeated a Democratic effort Tuesday to obtain any information the Justice Department has on possible conflicts, ethical violations or improper connections to Russia by President Donald Trump and his associates. The committee’s Republican chairman, Bob Goodlatte, opposed the resolution, even as he acknowledged the Justice Department hasn’t acted on his own request for a briefing on alleged Russian interference with the U.S. election and potential ties to the Trump campaign." He said he'll be sending a letter to Attorney General Jeff Sessions requesting him to pursue "all legitimate investigative leads" into those matters.

Source:
WAITING FOR NEWS CYCLE TO REFRESH
Trump Holds Off on New Travel Ban
3 hours ago
THE LATEST

"President Donald Trump won’t sign a revised travel ban on Wednesday as had been anticipated, two senior administration officials confirmed. One of the officials indicated that the delay was due to the busy news cycle, and that when Trump does sign the revised order, he wanted it to get plenty of attention."

Source:
BUT THEY MUST PAY
Donald Trump Affirms Support For NATO
14 hours ago
UPDATE

Near the end of his speech Tuesday, Donald Trump made a firm proclamation affirming his support for NATO. "We strongly support NATO, an alliance forged through the bonds of two World Wars that dethroned fascism, and a Cold War that defeated communism," Trump said. However, he continued on, "our partners must meet their financial obligations."

UNITES GOP
Obamacare Repeal Portion Lacks Specifics
15 hours ago
UPDATE

In his address to a joint session of Congress, Donald Trump called on the two chambers "to repeal and replace Obamacare with reforms that expand choice, increase access, lower costs, and at the same time, provide better Healthcare." The entire section of Republican members of Congress united in a standing ovation, while Democrats sat silently, with some even giving a thumbs down to the cameras. At one point, House Minority Leader Nancy Pelosi was shown shaking her head in disapproval. While Trump called for the repeal and replacement of Obamacare, he failed to give any specifics, though he did say those with preexisting conditions should have access to care and give flexibility back to the states.

×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login